Company News5 Nov 2026
Resolution Therapeutics
Resolution Therapeutics Reports Positive Interim EMERALD Data for RTX001 in Liver Disease
Resolution Therapeutics has reported six-month interim Phase I/II EMERALD data for RTX001, an engineered macrophage therapy for end-stage liver disease. Against an external control, the first nine patients showed a 42% relative risk reduction in death, liver transplant or hepatic decompensation. The company plans a pivotal US trial, with a pre-IND meeting with the FDA scheduled for December 2026.
View CompanySource: Resolution Therapeutics (press release)